Interpreting Ambulatory Monitoring

Documents to Request

• Complete ambulatory monitoring report with all pages
• Representative rhythm strips (normal sinus, abnormal events, symptom-correlated events)
• Patient symptom diary with timestamps
• Full disclosure data access (if available for independent review)
• Prior ambulatory monitoring reports for comparison
• Current medication list
• Recent ECG for baseline comparison
• Echocardiogram (structural context)
• Sleep study results if sleep-related arrhythmia suspected

Step 1: Device Selection Appropriateness Assessment

Device-to-Indication Matching (HRS Consensus):

Document: Was the selected device appropriate for the clinical question? If monitoring duration was insufficient to capture symptoms, recommend extended monitoring.

Step 2: Baseline Rhythm and Rate Analysis

Heart Rate Summary:

• Minimum HR with time and rhythm at minimum
• Maximum HR with time, activity, and rhythm at maximum
• Average HR over the recording period
• Heart rate variability (SDNN if reported — reduced SDNN < 50 ms associated with increased cardiac mortality)

Baseline Rhythm Assessment:

• Predominant rhythm: normal sinus, sinus bradycardia, sinus tachycardia, atrial fibrillation, atrial flutter, paced
• Sinus node function: appropriate rate variability, chronotropic response to activity
• AV conduction: PR interval consistency, presence of AV block episodes (first-degree, Mobitz I, Mobitz II, complete)
• Pauses: longest R-R interval, duration, mechanism (sinus pause, sinus arrest, AV block)

Pause Significance:

Step 3: Arrhythmia Event Analysis and Quantification

Supraventricular Events:

• Isolated PACs: count total, calculate burden (% of total beats)
• PAC burden > 10,000/day or > 10% associated with increased AF risk and cardiomyopathy
• SVT episodes: number, duration, peak rate, mechanism if identifiable (AVNRT, AVRT, AT)
• Atrial fibrillation: total burden (hours or % of recording time), longest episode, average ventricular rate during AF
• Atrial flutter: episodes, rate, duration

AF Burden Quantification:

Ventricular Events:

• Isolated PVCs: total count, burden (% of total beats)
• PVC burden > 10–15% associated with PVC-induced cardiomyopathy
• PVC morphology: uniform (single focus) vs. multiform
• Couplets: frequency
• NSVT episodes: number, duration (beats), rate
• Sustained VT (≥ 30 seconds or hemodynamically unstable): URGENT — report immediately
• R-on-T phenomenon: flag as high risk for VF

PVC Burden Significance:

Step 4: Symptom-Rhythm Correlation

Correlation Categories:

1. Positive correlation: Symptom occurred simultaneously with arrhythmia → arrhythmia is the cause
2. Negative correlation: Symptom occurred during normal sinus rhythm → arrhythmia is NOT the cause (equally important diagnostically)
3. Non-diagnostic: Symptoms occurred but no interpretable rhythm at that time, or no symptoms occurred during monitoring

Document for each diary entry:

• Timestamp of symptom
• Rhythm at that exact time
• Heart rate at that time
• Correlation conclusion

If no symptoms occurred during monitoring: State explicitly — "No patient-activated events during the monitoring period; study non-diagnostic for symptom-rhythm correlation. Consider extended monitoring."

Step 5: Structured Report and Recommendations

Report Template:

1. Indication for monitoring
2. Device type and total recording duration (analyzable %)
3. Predominant rhythm
4. Heart rate summary: minimum, maximum, average
5. Supraventricular events: PAC count/burden, SVT episodes (type, rate, duration), AF burden
6. Ventricular events: PVC count/burden, morphology, couplets, NSVT, sustained VT
7. Conduction abnormalities: AV block episodes, pauses (longest, mechanism)
8. ST-segment changes (if monitored)
9. Symptom-rhythm correlation
10. Comparison with prior study
11. Conclusions and recommendations

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the arrhythmia burden quantified (not just "present" or "absent")?
2. Is symptom-rhythm correlation addressed for every diary entry?
3. Are PVC and PAC burdens calculated as percentage of total beats?
4. Are high-risk findings (sustained VT, long pauses, high AF burden) flagged?
5. Is device appropriateness assessed for the clinical question?

Quality Audit

• Device type and recording duration documented
• Analyzable time percentage reported
• Predominant rhythm identified
• Heart rate summary with minimum, maximum, and average
• Supraventricular event quantification (PAC count and burden %)
• AF burden calculated as hours and/or percentage of recording
• Ventricular event quantification (PVC count and burden %)
• PVC morphology described (uniform vs. multiform)
• NSVT episodes documented with rate and duration
• Pauses documented with duration and mechanism
• Symptom-rhythm correlation addressed for every diary entry
• High-risk findings flagged with urgency level
• Comparison with prior monitoring study if available
• Recommendations include next steps (extended monitoring, echo, ablation, device)

Guidelines

1. Always quantify arrhythmia burden as a percentage of total beats — qualitative terms like "frequent" or "occasional" are clinically insufficient.
2. PVC burden > 10% warrants echocardiographic screening for PVC-induced cardiomyopathy, and burden > 15% should prompt ablation evaluation.
3. AF burden assessment requires documenting total AF duration as a proportion of recording time — single-episode duration alone does not capture intermittent burden.
4. Symptom-rhythm NEGATIVE correlation (symptoms during sinus rhythm) is diagnostically valuable and should be clearly reported.
5. Pauses ≥ 3 seconds during wakefulness require clinical evaluation for sinus node dysfunction or AV block regardless of symptoms.
6. When monitoring fails to capture symptoms (non-diagnostic study), recommend the appropriate next-step device based on symptom frequency.
7. In cryptogenic stroke patients, AF detection requires at least 30 seconds of continuous AF per current guidelines to warrant anticoagulation — shorter episodes remain an area of active study.
8. Heart rate variability metrics should be reported when available, as reduced SDNN is an independent predictor of cardiac mortality in post-MI and HF patients.